Head of Biology
Dr. Celina Zerbinatti joined E-Scape Bio as Head of Biology in 2018, bringing extensive expertise in apoE and lipid biology, together with 15 years of pharma experience in assay development, disease models and biomarker discovery in the context of drug development for neurodegenerative diseases. Dr. Zerbinatti is responsible for overseeing pre-clinical efforts to support screening, lead identification and optimization, as well as biology activities to assist development of E-Scape Bio's clinical programs.
Dr. Zerbinatti was most recently an Entrepreneur-in-Residence with the Dementia Discovery Fund, where she led early seed projects for NewCo creation, and supported assessment of new investment opportunities. Prior to her EIR role, Dr. Zerbinatti was Vice President, Neurobiology at Evotec AG, where she was responsible for the scientific and operational oversight of a broad drug discovery alliance with the CHDI foundation on Huntington's disease. Dr. Zerbinatti also interfaced with Evotec's Innovate segment to advance early-stage programs within the Neuroscience R&D portfolio.
Before joining Evotec, Dr. Zerbinatti gained extensive drug discovery experience at Merck Research Laboratories. As an Associate Director in the Neuroscience Department, she led multiple target validation efforts and preclinical drug discovery teams, focusing primarily on targets genetically linked to Alzheimer's and other neurodegenerative diseases. Dr. Zerbinatti obtained her PhD at the University of Sao Paulo, Brazil, and completed her postdoctoral training at Washington University School of Medicine, working on the role of apoE and apoE receptors in the pathophysiology of Alzheimer's disease with Dr. Guojun Bu.